Owen Wolkowitz

Dr. Owen Wolkowitz


Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
OWOwen Wolkowitz
Owen Wolkowitz
SMSynthia H. Mellon
Synthia H. Mellon
EEElissa S. Epel
Elissa S. Epel
JLJue Lin
Jue Lin
FDFirdaus S. Dhabhar
Firdaus S. Dhabhar
EBElizabeth H. Blackburn
Elizabeth H. Blackburn
Depression is associated with an unusually high rate of aging-related illnesses and early mortality. One aspect of “accelerated aging” in depression may be shortened leukocyte telomeres. When telomeres critically shorten, as often occurs with repeated mitoses or in response to oxidation and inflammation, cells may die. Indeed, leukocyte telomere shortening predicts early mortality and medical illnesses in non-depressed populations. We sought to determine if leukocyte telomeres are shortened in Major Depressive Disorder (MDD), whether this is a function of lifetime depression exposure and whether this is related to putative mediators, oxidation and inflammation. Leukocyte telomere length was compared between 18 unmedicated MDD subjects and 17 controls and was correlated with lifetime depression chronicity and peripheral markers of oxidation (F2-isoprostane/Vitamin C ratio) and inflammation (IL-6). Analyses were controlled for age and sex. The depressed group, as a whole, did not differ from the controls in telomere length. However, telomere length was significantly inversely correlated with lifetime depression exposure, even after controlling for age (p<0.05). Average telomere length in the depressed subjects who were above the median of lifetime depression exposure (≥9.2 years' cumulative duration) was 281 base pairs shorter than that in controls (p<0.05), corresponding to approximately seven years of “accelerated cell aging.” Telomere length was inversely correlated with oxidative stress in the depressed subjects (p<0.01) and in the controls (p<0.05) and with inflammation in the depressed subjects (p<0.05). These preliminary data indicate that accelerated aging at the level of leukocyte telomeres is proportional to lifetime exposure to MDD. This might be related to cumulative exposure to oxidative stress and inflammation in MDD. This suggest that telomere shortening does not antedate depression and is not an intrinsic feature. Rather, telomere shortening may progress in proportion to lifetime depression exposure.

1 August 2015 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Closed access
DLDaniel Lindqvist
Daniel Lindqvist
EEElissa S. Epel
Elissa S. Epel
SMSynthia H. Mellon
Synthia H. Mellon
BPBrenda W. Penninx
Brenda W. Penninx
DRDóra Révész
Dóra Révész
OWOwen Wolkowitz
Owen Wolkowitz

1 April 2010 in Depression and Anxiety
Verified
Journal Article
Open access
PDF file
OWOwen Wolkowitz
Owen Wolkowitz
EEElissa S. Epel
Elissa S. Epel
VRVictor I. Reus
Victor I. Reus
SMSynthia H. Mellon
Synthia H. Mellon
Depression has been likened to a state of “accelerated aging,” and depressed individuals have a higher incidence of various diseases of aging, such as cardiovascular and cerebrovascular diseases, metabolic syndrome, and dementia. Chronic exposure to certain interlinked biochemical pathways that mediate stress‐related depression may contribute to “accelerated aging,” cell damage, and certain comorbid medical illnesses. Biochemical mediators explored in this theoretical review include the hypothalamic–pituitary–adrenal axis (e.g., hyper‐ or hypoactivation of glucocorticoid receptors), neurosteroids, such as dehydroepiandrosterone and allopregnanolone, brain‐derived neurotrophic factor, excitotoxicity, oxidative and inflammatory stress, and disturbances of the telomere/telomerase maintenance system. A better appreciation of the role of these mediators in depressive illness could lead to refined models of depression, to a re‐conceptualization of depression as a whole body disease rather than just a “mental illness,” and to the rational development of new classes of medications to treat depression and its related medical comorbidities. Depression and Anxiety, 2010.

1 July 2013 in Brain, Behavior, and Immunity
Verified
Journal Article
Closed access
BRB.J. Rawdin
B.J. Rawdin
SMS.H. Mellon
S.H. Mellon
FDF.S. Dhabhar
F.S. Dhabhar
EEE.S. Epel
E.S. Epel
EPE. Puterman
E. Puterman
OWOwen Wolkowitz
Owen Wolkowitz

1 November 2014 in Brain, Behavior, and Immunity
Verified
Journal Article
Closed access
DLDaniel Lindqvist
Daniel Lindqvist
OWOwen Wolkowitz
Owen Wolkowitz
SMSynthia Mellon
Synthia Mellon
RYRachel Yehuda
Rachel Yehuda
JFJanine D. Flory
Janine D. Flory
FDFirdaus S. Dhabhar
Firdaus S. Dhabhar

31 March 2011 in Dialogues in clinical neuroscience
Verified
Journal Article
Open access
OWOwen Wolkowitz
Owen Wolkowitz
VRVictor I Reus
Victor I Reus
SMSynthia H Mellon
Synthia H Mellon
Major depressive disorder (MDD) is associated with a high rate of developing serious medical comorbidities such as cardiovascular disease, stroke, dementia, osteoporosis, diabetes, and the metabolic syndrome. These are conditions that typically occur late in life, and it has been suggested that MDD …